Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline includes RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Revolution Medicines Inc - Ordinary Shares

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Revolution Medicines (RVMD – Research Report), Roche Holding AG (...

Analysts Conflicted on These Healthcare Names: Revolution Medicines (RVMD), Roche Holding AG (OtherRHHVF) and Incyte (INCY)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CVS Health (CVS – Research Report), Revolution Medic...

Analysts’ Top Healthcare Picks: CVS Health (CVS), Revolution Medicines (RVMD)

Guggenheim analyst Michael Schmidt reiterated a Buy rating on Revolution Medicines today and set a price target of $160.00. Schmidt covers the Heal...

Guggenheim Keeps Their Buy Rating on Revolution Medicines (RVMD)

Revolution Medicines, Inc. ($RVMD) announced an update on their ongoing clinical study. Study Overview Revolution Medicines, Inc. is running a Phas...

Revolution Medicines Advances RMC-5127 KRAS Program, Extending Its Oncology Reach

Pharma giant Merck ($MRK) is targeting $70 billion in revenue from new growth drivers by the mid-2030s, as the company accelerates the launch of ne...

Merck Sees $70B Revenue Potential From New Growth Drivers by Mid-2030s

Analysts have been eager to weigh in on the Healthcare sector with new ratings on PTC Therapeutics (PTCT – Research Report), Revolution Medicines (...

Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), Revolution Medicines (RVMD) and West Pharmaceutical Services (WST)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Delcath Systems (DCTH – Research Report), Exagen (XG...

Analysts Offer Insights on Healthcare Companies: Delcath Systems (DCTH), Exagen (XGN) and Revolution Medicines (RVMD)

Unusual trading volume signals that a stock is moving well above or below its average activity, often driven by major news, upcoming catalysts, or ...

Top 5 Trending Stocks by Unusual Trading Volume, 1/10/26

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD – Research Report) and Gl...

Analysts’ Top Healthcare Picks: Revolution Medicines (RVMD), Globus Medical (GMED)

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Revolution Medicines today and set a price target of $98.00. Stranahan...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RVMD	$95.97	-1.22%	2.42M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RVMD	$95.97	-1.2%	2.42M
3
4
5
6

RVMD

RVMD

Dividend Overview

Get Revolution Medicines Inc - Ordinary Shares Data in Excel

Get Revolution Medicines Inc - Ordinary Shares Data in Excel